

SCIENTIFIC REPORTS



OPEN

Detection of functional protein domains by unbiased genome-wide forward genetic screening

Mareike Herzog¹, Fabio Puddu¹, Julia Coates¹, Nicola Geisler¹, Josep V. Forment^{1,2} & Stephen P. Jackson¹

Establishing genetic and chemo-genetic interactions has played key roles in elucidating mechanisms by which certain chemicals perturb cellular functions. In contrast to gene disruption/depletion strategies to identify mechanisms of drug resistance, searching for point-mutational genetic suppressors that can identify separation- or gain-of-function mutations has been limited. Here, by demonstrating its utility in identifying chemical-genetic suppressors of sensitivity to the DNA topoisomerase I poison camptothecin or the poly(ADP-ribose) polymerase inhibitor olaparib, we detail an approach allowing systematic, large-scale detection of spontaneous or chemically-induced suppressor mutations in yeast or haploid mammalian cells in a short timeframe, and with potential applications in other haploid systems. In addition to applications in molecular biology research, this protocol can be used to identify drug targets and predict drug-resistance mechanisms. Mapping suppressor mutations on the primary or tertiary structures of protein suppressor hits provides insights into functionally relevant protein domains. Importantly, we show that olaparib resistance is linked to missense mutations in the DNA binding regions of PARP1, but not in its catalytic domain. This provides experimental support to the concept of PARP1 trapping on DNA as the prime source of toxicity to PARP inhibitors, and points to a novel olaparib resistance mechanism with potential therapeutic implications.

In model organisms, genetic screens have long been used to characterize gene functions, to define gene networks, and to identify the mechanism-of-action of drugs^{1–4}. The genetic relationships identified by such screens have been shown to involve positive and negative feedbacks, backups and cross-talks that would have been extremely difficult to discover using other approaches⁵. Currently, the large majority of reported screens in model organisms and in mammalian-cell systems have used gene-deletion libraries and/or methodologies to inactivate gene functions, such as short-interfering RNA, CRISPR-Cas9 or transposon-mediated mutagenesis^{6,7}. While powerful, such approaches usually identify loss-of-function phenotypes, and only rarely uncover separation-of-function or gain-of-function mutations. Gene overexpression screens have successfully identified gain-of-function alleles, but these screens often involve non-physiological protein levels. This limitation is significant because such separation- or gain-of-function mutations – which can arise spontaneously or via the action of genotoxic agents – can dramatically affect cell functions or cellular response to chemicals, and can have profound impacts on human health and disease^{8,9}. Suppressor screens, either based on lethal genetic deficiencies and/or the use of drugs, have also facilitated the characterization of functionally relevant protein domains and sites of post-translational protein modification through the identification of relevant single nucleotide DNA variants (SNV)s¹⁰.

In their simplest experimental setup, suppressor screens based on point-mutagenesis rely on four tools: (i) a genetically amenable organism or cell; (ii) a selectable phenotype; (iii) a method to create a library of mutants; and (iv) a method to identify mutations driving the suppressor phenotype amongst all the mutations in the library. Reflecting their relative amenability, these screens have mostly been carried out in microorganisms, either bacteria or yeasts, both of which benefit from the ability to survive in a stable haploid state. Despite not being strictly essential for such studies, a haploid state facilitates the identification of loss-of-function or separation-of-function recessive alleles, which would be masked in a heterozygous diploid cell state¹¹. While

¹The Wellcome/CRUK Gurdon Institute and Department of Biochemistry, University of Cambridge, Tennis Court Road, CB2 1QN, Cambridge, UK. ²Present address: AstraZeneca, Oncology DNA damage response group, Hodgkin Building, 310 Cambridge Science Park, Milton Road, CB4 0WG, Cambridge, UK. Mareike Herzog and Fabio Puddu contributed equally to this work. Correspondence and requests for materials should be addressed to J.V.F. (email: j.forment@gurdon.cam.ac.uk) or S.P.J. (email: s.jackson@gurdon.cam.ac.uk)




Figure 1. Experimental workflow for a suppressor screen. The typical workflow of a suppressor screen using *S. cerevisiae* (left) or mouse embryonic stem cells (right) is depicted. Details of differences between the two systems are illustrated where appropriate. Variation in mutation numbers for an organism can be due to the choice of background strain, mutagenizing agent and other experimental factors.

the first three tools mentioned above are often amenable to a researcher, the lack of fast and efficient methods to bridge the knowledge-gap between phenotype and genotype has discouraged the widespread implementation of suppressor screens based on point-mutagenesis. Indeed, until recently, recessive suppressor alleles could only be identified by labor-intensive methods involving genetic mapping and cloning in yeast, whereas the natural diploid state of mammalian cells largely precluded straightforward SNV suppressor screens in such systems.

Here, we describe an approach to overcome the above limitations that is based on sequencing of genomic DNA extracted from various independent suppressor clones, followed by bioinformatic analysis. With small adaptations, this method can be applied to both the budding yeast *Saccharomyces cerevisiae* and other haploid model organisms, as well as to haploid mammalian cells (Fig. 1). To highlight the utility of this approach, we describe its application to study resistance to the anti-cancer drugs camptothecin or olaparib, leading to the identification of various mutations in yeast *TOP1* and in mouse *Parp1*, respectively. Importantly, we establish that drug target identification and mechanisms of drug resistance can be unveiled without *a priori* knowledge of the drug target. Furthermore, if a sufficient number of chemical-genetic suppressors is screened, this method also allows identification of functional protein domains required to drive drug sensitivity and resistance.

Results

Identification of *TOP1* mutations conferring camptothecin resistance. To demonstrate the utility of the procedure described above, we sought to identify mutations imparting resistance to camptothecin, a DNA topoisomerase 1 inhibitor^{12–14}. To do this, we employed yeast strains carrying mutations inactivating pathways required for camptothecin resistance. These specific mutations (*rad50S*, *sae2-F267A*, *rtt107Δ*, *tof1Δ*, *sae2Δmre11-H37R-tel1Δ*) were chosen for their ability to induce camptothecin hypersensitivity^{15–18}. To maximize the variety of potential mutations driving drug resistance, two of the five strains used were mutagenized with ethyl methane sulfonate (EMS), an alkylating agent that induces SNVs¹⁹, before plating them in the presence of camptothecin. In all cases, camptothecin-resistant colonies were readily detectable after 2–3 days of growth at 30 °C.

Genomic DNA sequencing of the resistant clones highlighted *TOP1* as the gene carrying the largest number of unique mutations in our dataset, as expected for it being the drug target. The second most mutated gene — *PDR1* that is known to regulate a pathway of multi-drug resistance²⁰ — carried 11 unique mutations, 10 of which did not co-occur with mutations in *TOP1*, whereas all the mutations found in the third most mutated gene (*GLT1*) co-occurred with mutations in either *TOP1* or *PDR1*, suggesting that *GLT1* mutations do not drive camptothecin resistance *per se* (Fig. 2a and data not shown). It is possible that the unexpectedly high frequency of *GLT1* mutations could arise from them somehow enhancing cell survival to EMS, as these mutations are only found in EMS-mutagenized samples. Globally, out of the 251 yeast strains sequenced, 191 contained one or more mutation in *TOP1* (Fig. 2b, light yellow). Furthermore, by manual inspection, we found that 27 additional strains carried mutations in *TOP1* (Fig. 2b, dark yellow); the inability to automatically detect these mutations was caused by the fact that these strains were either not pure clones, or they carried large (>25 bp) deletions in *TOP1* (Fig. 2b and Supplementary Figure S1). To the list of *TOP1*-mutated camptothecin-resistant strains, we added another 38 strains bearing *TOP1* mutations that we had identified in previous, published screens^{16,21}, bringing the total number of *TOP1* mutants analyzed to 256.




Figure 2. Screening for camptothecin resistance highlights *TOP1* and its functional domains. **(a)** Genes found mutated in screenings for camptothecin resistance sorted by the number of non-synonymous, independent mutations identified in each gene. **(b)** Fraction of strains identified as mutated in *TOP1* by initial analysis (light yellow) and upon manual inspection of the *TOP1* gene (dark yellow); blue represents clones where no *TOP1* mutation was identified. **(c)** Mutation types identified in EMS mutagenized samples and non-EMS mutagenized samples. Location of nonsense **(d)**, frameshift **(e)** and missense **(f)** mutations in the *TOP1* gene with respect to the primary protein sequence. Mutations identified in EMS-treated samples are colored red, while those from non-mutagenized samples are colored green.

Missense, nonsense and frameshift *TOP1* mutations were roughly equally represented in the non-mutagenized samples. However, where samples had been mutagenized with EMS the vast majority of mutations were nonsense or missense base substitutions (Fig. 2c). In the few cases in which the same suppressor clone contained missense and nonsense mutations in *TOP1*, the suppressive effect was attributed to the gained STOP codon.

When the positional distribution of each mutation type was plotted, nonsense and frameshift mutations were shown to be quite evenly distributed along the length of the *TOP1* open reading frame (Fig. 2d and e). The prediction is that such mutations either result in null alleles – as the prematurely-terminated messenger RNA (mRNA) would be degraded by nonsense-mediated decay mechanisms²² – or would give rise to an unstable protein or a truncated version that could retain partial activity. Since the Y727 residue is essential for the catalytic activity of Top1, truncation before this residue is predicted to produce a non-functional protein^{23,24}. As might be expected, the distribution of nonsense mutations loosely correlated with them arising from codons in the open reading frame that only required one nucleotide change to change them to a STOP codon (Supplementary Figure S1). Notably, the observed enrichment of frameshifts near the 5' end of the *TOP1* transcript was localized to an 8-nucleotide homopolymeric adenine tract that is presumably particularly susceptible to mutagenesis (Supplementary Figure S1).

In striking contrast to the situation with nonsense or frameshift mutation, missense mutations were localized to specific regions of the *TOP1* protein-coding sequence, overlapping with known functional domains of Top1. Indeed, the vast majority of mutations identified localized within three distinct regions of the larger DNA binding and catalytic domain, while a minority was located in the smaller C-terminal domain, essential for catalysis (Fig. 2f).

Functional consequences of the amino acid residue changes induced by missense mutations were assessed by using PROVEAN and PredicProt^{25,26}. These tools use chemical properties of amino acid residues and phylogenetic conservation to predict whether or not a particular substitution is likely to be functionally tolerated by the protein analyzed. Both these methods suggested that the vast majority of the *TOP1* mutations we identified in camptothecin resistant strains were likely to produce deleterious effects (PROVEAN score < -2.5; PredictProtein score > 50) (Fig. 3a). Notably, missense mutations located in the C-terminal domain of Top1 affected both conserved and non-conserved residues and were primarily positioned in the vicinity of the catalytic residue Y727, although three substitutions were closer to the C-terminus of the protein (Fig. 3b).




Figure 4. A screen for olaparib resistance indicates critical functional residues in PARP1. (a) Genes found mutated in the olaparib resistant clones sorted by the number of non-synonymous, independent mutations per gene. (b) Fraction of strains identified by analysis workflow to carry a mutation in *Parp1*. (c) Locations of mutations with respect to the protein sequence. The lower panel shows the distribution of missense mutations, while the upper panel contains all mutations likely to lead to a loss of PARP1 protein: nonsense, frameshift and splice acceptor/donor nucleotide mutations as well as mutations of the start codon. (d) The likelihood of being deleterious of *Parp1* missense mutations as predicted by PredictProtein (y-axis; a score above 50 is considered deleterious) and PROVEAN (x-axis; a score below -2.5 is considered deleterious). Datapoints are coloured by the domain the missense mutations occur in: Light blue, dark blue and green are the three Zinc fingers, respectively, purple denotes the BRCT domain, while red indicates the WGR domain.

highlighted how such an analysis would have identified PARP1 as the likely prime driver of olaparib sensitivity without any knowledge about the drug's mechanism-of-action (see below for further discussion).

Of the *Parp1* mutations we detected, more than half led to premature termination codons, splice acceptor/donor, or frameshift mutations, which would presumably lead to the production of aberrant mRNAs subject to nonsense-mediated decay and/or the generation of unstable, truncated PARP1 protein. As we previously noted for premature-termination mutations in yeast *TOPI*, these mutations did not cluster in any particular domain(s) of the *Parp1* open reading frame (Fig. 4c). Furthermore, similar to what we observed in yeast, EMS treatment resulted in an overrepresentation of single nucleotide variants, compared to frameshift mutations (Fig. 4c).

Strikingly, missense mutations detected in *Parp1* were more frequent in the N-terminal part of the protein, where the DNA-binding domains reside, while no such mutations were observed in the catalytic domain (Fig. 4c). Analysis of PARP1 protein levels indicated that other than G400R and A610V, which resulted in complete loss or marked reduction of the PARP1 protein product, no other of the identified missense mutations impacted on PARP1 protein stability (Fig. 5a, Supplementary Figure S3). Computational predictions for the likely consequences of these remaining missense mutations on protein structure and function suggested that all of them were functionally deleterious (Fig. 4d). Since all these missense mutations localized within domains known to be involved in DNA binding, we examined their locations relative to the DNA-protein interface as defined by previously published PARP1 structures^{32,33} (Fig. 5b). Notably, most of the missense mutations affecting residues in the DNA binding domains clustered at the DNA-protein interface, and did so in proximity to residues that make key DNA contacts³³.

Without any a priori knowledge about how olaparib causes cell toxicity, the above data would have suggested that such toxicity is largely driven by a mechanism connected to PARP1 DNA binding. To test this idea, we assessed the missense mutations identified in the DNA binding domains of PARP1 for their potential effects on




Figure 5. Missense mutations interfere with PARP1 DNA binding. **(a)** Olaparib resistant clones were assayed for the presence of PARP1 protein. A representative selection is shown, along with the *Parp1* mutation carried by each clone: unknown indicates that no mutation could be automatically detected. Upon further, manual inspection, the mutations identified in brackets were discovered. More clones can be seen in Supplementary Figure 3a. **(b)** Location of missense mutations that do not lead to a loss of PARP1 protein are indicated on partial PARP1 structures of the ZN2 domain by itself (PDB code 3ODC) and the PARP1 protein except ZN2 and the BRCT domain (PDB code 4DQY). **(c)** Clones carrying mutations that do not lead to loss of/reduction in PARP1 protein were assayed for the protein's ability to bind a double-stranded DNA oligonucleotide. One experiment each was quantified. All blots can be viewed in Supplementary Figure 3b. **(d)** Cells with either wild type or mutant PARP1 protein were assayed for their ability to PARylate. Cells were either left untreated or treated with hydrogen peroxide (H₂O₂). Wild type cells were also treated with olaparib overnight before H₂O₂ treatment. **(e)** Summary of olaparib resistant clone analysis. The inner circle shows the mutations that have been identified in every clone (dark yellow signifies mutations identified by manual inspection of the data). The outer circle shows the respective effect on PARP1 protein accounting for the mechanism of olaparib resistance.

the ability of PARP1 to bind a double-stranded DNA oligonucleotide. Significantly, this analysis revealed that all the point mutants that did not reduce PARP1 levels showed reduced levels of DNA binding when compared to the wild-type PARP1 protein (Fig. 5c, Supplementary Figure S3). Consistent with PARP1 DNA binding triggering its auto-modification by poly ADP-ribose, we found that the PARP1 S568F mutation, which impairs DNA binding, did not exhibit evidence of PARylation when cells were treated with hydrogen peroxide (Fig. 5d). These findings were therefore in accord with the fact that toxicities of PARP inhibitors such as olaparib are linked to their ability to trap PARP1 on DNA by blocking its catalytic activity³⁰.

The last clone without an assigned mutation driving resistance to olaparib (C1) may also carry one or more mutations in the non-exonic regions of the *Parp1* gene, or epigenetic modifications altering *Parp1* expression, since we could not detect the presence of PARP1 in protein extracts (Fig. 5a). Taken together, these results are consistent with a model in which olaparib resistance can arise either from loss of PARP1 or from its decreased ability to bind DNA (Fig. 5e).

Discussion

Various approaches have been described for systematic identification of genetic and chemo-genetic interactions. Until recently, this search has been largely conducted using approaches based on gene inactivation, either in arrayed or pooled assay formats. While these approaches have played crucial roles in determining gene-gene and gene-drug interactions, their limited power of resolution does not in general provide information regarding the functional protein domains relevant for the identified interaction. While transposon-based mutagenesis and dense CRISPR gRNA approaches have recently been shown to provide some information at the domain level, this approach is only applicable to loss-of-function mutations, and is biased towards C-terminal domains of proteins³⁴. In contrast, SNV based approaches can provide a higher level of resolution, and in many cases produce unanticipated results^{10,35–37}. Lack of rapid and facile procedures to bridge the phenotype-to-genotype gap has until recently, however, precluded the use of these techniques on a high-throughput scale.

The approach we have described allows the identification of SNVs driving drug resistance or resistance to essentially any selective growth condition in a systematic and unbiased way (other than any bias imposed by the mutagenic agent of choice). Importantly, this approach can equally be applied to yeast and to more complex eukaryotes, bringing the power of high-resolution haploid genetic screens to mammalian systems. It should however be noted that certain limitations of haploid genetics, such as the inability to formally distinguish between recessive and dominant alleles, will also apply to mammalian systems. While we acknowledge that we have carried out our screens with strong selectable cell-viability phenotypes, we envisage applicability in more complex scenarios, for example involving FACS-based selection or cell migration, motility or attachment assays. Highlighting this potential, our results show how, with no previous knowledge, Top1 and PARP1 would have been identified as the most likely targets for the drugs camptothecin and olaparib, respectively.

Toxicity to PARP inhibitors was initially linked to the involvement of PARP1 in the repair of single-strand DNA breaks^{38,39}, but more recent data challenged this view⁴⁰. The fact that loss of PARP1 drives resistance to PARP inhibitors in wild-type genetic backgrounds⁴¹ indeed suggests that inhibition of PARP1 catalytic activity — and not the accumulation of unrepaired DNA lesions — is the major effector of toxicity in such genetic backgrounds. Indeed, recent findings suggest that PARP1 trapping onto DNA, caused by inhibition of its catalytic activity, is the main cause of toxicity³¹. Our data further support this model, as all the suppressor clone variants which we identified that did not result in loss of PARP1 protein negatively affected its binding to DNA. Preventing PARP1 binding to DNA thus appears to be sufficient to circumvent the toxicity of PARP inhibitors, at least in homologous-recombination proficient cells; and the fact that we identified no mutants specifically defective in catalytic function reinforces the idea of trapped PARP1 as the main cytotoxic lesion for olaparib in wild-type mammalian cells. Further work in a diploid setting will be required to demonstrate whether the DNA-binding deficient alleles isolated are recessive, and that the PARP1-olaparib complex indeed acts as a dominant negative entity. This may not only be important for our understanding of how PARP inhibitors function but also for understanding mechanisms of intrinsic or evolved tumor resistance towards such clinical agents. In particular, it will be interesting to determine whether olaparib resistance in patients with BRCA1/2 mutant cancers can be driven by loss of PARP binding to DNA.

As exemplified by our analyses of Top1 and PARP1, the level of detail on critical functional domains and residues increases with the number of samples sequenced. Because of their genome size, screens based in mammalian systems require greater sequencing power than screens conducted in simpler organisms such as yeast. Moreover, as compared to yeasts, the more complex genome architecture in mammalian systems — where there is more intergenic DNA, a larger number of genes and an abundance of intronic sequences — increases the chances of isolating variants affecting protein levels, rather than protein function. One solution to bypass such issues will be to run two-tiered screens, initially using whole exome sequencing on a subset of suppressors in order to identify top gene hits driving resistance, and then using targeted exome sequencing to test the rest of the samples, either through analysis of various individual clones or bulk sequencing of the resistant population. In addition, we can envision alternative scenarios where a gene identified in an initial screen could be marked/tagged in a way to allow selection of mutations that affect protein function but not protein levels. This approach can also be combined with CRISPR-Cas9-mediated *in vivo* targeted mutagenesis, via a library of gRNAs directed towards the exonic regions of the gene (Pettitt *et al.*, BioRxiv <https://doi.org/10.1101/203224>). We anticipate that such developments, along with expected further increases in sequencing throughput and associated cost reductions, will pave the way for hitherto unprecedented genetic analyses on comprehensive and systematic scales.

Methods

Yeast suppressors of camptothecin sensitivity. *S. cerevisiae* strains used were derived from W303. All gene deletions were introduced by using one-step gene disruption, and were confirmed by PCR and whole-genome sequencing. Full genotypes of strains are described in Supplementary Table 1. Standard growth conditions (1% yeast extract, 2% peptone, 2% glucose, 40 mg/l adenine) were used. Strains YFP1001 and YFP1073 were mutagenized by adding 4.5% ethyl methane sulfonate (EMS) to liquid cultures in logarithmic growth-phase, pelleted by centrifugation and then resuspended in 50 mM K-phosphate buffer for 10 minutes, followed by EMS inactivation with 1 volume of 10% sodium thiosulfate. Suppressors were obtained by plating each strain on 10 YPD plates supplemented with 5 µg/ml of camptothecin (approximately 10⁷ cells per plate). Resistant colonies were picked after 2–3 days of growth at 30°C and isolated by streaking on YPD plates. Suppression was confirmed by retesting camptothecin sensitivity of the isolated strains. Confirmed suppressors were processed for DNA extraction shortly thereafter, in parallel with 2–3 colonies of the initial strain (Fig. 1a).

Mouse embryonic stem cell suppressors of olaparib sensitivity. Haploid mouse AN3-12 embryonic stem cells (mESCs)^{42,43} were used for all the experiments and were free from mycoplasma. Cells were grown in DMEM high glucose (Sigma) supplemented with glutamine, fetal bovine serum, streptomycin, penicillin, non-essential amino acids, sodium pyruvate, 2-mercaptoethanol and Leukemia inhibitory factor (LIF). All plates and flasks were gelatinized before cell seeding.

Cell sorting for DNA content was performed on mESCs by using a MoFlo flow sorter (Beckman Coulter) after staining with 15 µg/ml Hoechst 33342 (Invitrogen). The 1n peak was purified to enrich for haploid mESCs.

Mutagenesis with EMS was performed as described previously⁴⁴ with the following adjustments: after cell sorting, haploid-enriched cells were grown in DMEM plus LIF for overnight EMS treatment. After EMS treatment, cells were cultured for five passages in DMEM plus LIF and plated into 6-well plates at a density of 5 × 10⁵ cells per well. Cells were then treated with 6 µM of olaparib (AZD2281; Stratech Scientific Ltd.) for 6 days, supplying new medium with olaparib daily. Cells were then grown for another four days without olaparib until mESC colonies could be isolated.

Genomic DNA isolation. *S. cerevisiae* DNA isolation. Resistant colonies were inoculated in 1.8 ml of YPAD in 96-deep-well plates and grown for 48 hours. Pelleted cells were re-suspended in 500 μ l of spheroplasting solution (1 M sorbitol, 0.1 M EDTA, 14 mM 2-mercaptoethanol, 1 mg/ml RNase A, containing 5 mg/ml zymolyase) and incubated for 2 hours at 37 °C. Spheroplasts were subsequently re-suspended in 200 μ l of lysis buffer (80% ATL buffer [QIAGEN #19076], 10% Proteinase K [QIAGEN #19133] and 10% RNase A (10 mg/ml)) and incubated overnight (>16 h) at 56 °C. Genomic DNA was extracted from the resulting solution by using the Corbett X-Tractor Gene™ Robot with the following buffers: AL [QIAGEN #19075; diluted 50% with ethanol], DXW [QIAGEN #950154], DXF [QIAGEN #950163], and E [QIAGEN #950172] (Fig. 1a).

Mouse genomic DNA isolation. mESC clones were grown into 12-well plates. After trypsinising and resuspension in 200 μ l PBS and 200 μ l Buffer AL [QIAGEN], a proteinase K [QIAGEN, 20 μ l] and RNase [QIAGEN, 0.4 mg] digestion step was performed (incubating 10 min at 56 °C). After adding 200 μ l 96–100% ethanol the solutions were applied to QIAamp Mini spin columns following the QIAamp DNA Blood Mini Kit [QIAGEN] manufacturer's protocol from there. Genomic DNA was eluted from the columns using 200 μ l distilled water. A second elution was performed if the yield of the genomic DNA obtained was lower than 2 μ g. Genomic DNA was stored at –20 °C short-term before sequencing (Fig. 1a).

Illumina library preparation and sequencing. Extracted DNA was tested for total volume, concentration and total amount by using gel electrophoresis and the Quant-iT™ PicoGreen® dsDNA Assay Kit (ThermoFisher Scientific). Genomic DNA –500 μ g (yeast) or 1–3 μ g (mouse) – was fragmented to an average size of 100–400 bp (mouse) or 400–600 bp (yeast) by using a Covaris E210 or LE220 device (Covaris, Woburn, MA, USA), size-selected and subjected to DNA library creation via established Illumina paired-end protocols. Adaptor-ligated libraries were amplified and indexed via PCR. A portion of each library was used to create an equimolar pool comprising 45 indexed libraries for mouse samples, and 96 indexed libraries for yeast samples. For mouse whole-exome sequencing, pools were hybridized to SureSelect RNA baits (Mouse_all_exon; Agilent Technologies) (Fig. 1b).

Mouse libraries were sequenced at 15 samples per lane. Yeast libraries were sequenced at up to 96 samples per lane. Libraries were sequenced by using the HiSeq 2500 (Illumina) to generate 75 (mouse), or 100/125 (yeast) base paired-end reads according to the manufacturer's recommendations.

Analysis of DNA sequence data to identify suppressor mutations. *Alignment of DNA sequencing data.* Sequencing reads were aligned to the appropriate reference genome using BWA aln (v0.5.9-r16)⁴⁵. The *S. cerevisiae* S288c assembly (R64-1-1) from the Saccharomyces Genome Database was obtained from the Ensembl genome browser. For mouse samples, the *Mus musculus* GRCm38 (mm10) was used. Where appropriate, all lanes from the same library were merged into a single BAM file, and PCR duplicates were marked by using Picard Tools (Picard version 1.128). The quality of the sequencing data post-alignment was assessed by using SAMtools stats and SAMtools flagstats (1.1+htslib–1.1), plot-bamstats, bamcheck and plot-bamcheck⁴⁶ (Fig. 1c).

Variant calling, consequence annotation and filtering. SNVs and small insertions/deletions (INDELs) were identified using SAMtools mpileup (v.1.3)⁴⁶, followed by BCFtools call (v.1.3)⁴⁶. The following parameters were used for SAMtools mpileup: -g -t DP,AD -C50 -pm3 -F0.2 -d10000. Parameters for BCFtools call were: -vm -f GQ. All variants were annotated by using the Ensembl Variant Effect Predictor (VEP) v82⁴⁷. To exclude low quality calls, variants were filtered by using VCFtools vcf-annotate (v.0.1.12b)⁴⁸ with options -H -f +/q = 25/SnpGap = 7/d = 5, and custom filters were written to exclude variants with a Genotype Quality (GQ) score of less than 10. In the case of whole-exome sequencing data, variants called outside of targeted regions were excluded. INDELs were left-aligned using BCFtools norm⁴⁶.

Removal of background mutations. Variants that confer resistance are absent in the initial strain/cell line, as it is sensitive to the drug used. Bedtools intersect was therefore used to remove variants present in any *S. cerevisiae* control samples to eliminate variation of the background relative to the reference genome from the dataset. Variant calls from mouse samples were filtered by removing all variants identified in sequencing data of three olaparib-sensitive AN3-12 clones using VCFtools vcf-isec⁴⁸; INDELs were further verified by using the microassembly-based variant caller Scalpel⁴⁹. To address the high false positive rate in INDEL variant calls, only the INDELs that were identified by both variant callers and have passed the filters were retained.

Variant prioritization. Variants were prioritized by their Ensembl VEP⁴⁷ predicted consequence: we retained variants predicted to cause a frameshift, a premature stop codon, a missense mutation, a lost start/stop codon, a synonymous mutation, an in-frame insertion or deletion, and in the case of mouse data, those annotated to affect splice donor/acceptor bases. Genes were prioritized by ranking them by the number of distinct mutations identified in each gene.

Missense mutations identified in genes of interest were ranked by using predictions of PROVEAN/SIFT^{25,50–52} and PredictProtein²⁶. Scores below –2.5 for PROVEAN, above 50 for PredictProtein and below 0.05 for SIFT indicate likely deleterious consequences to protein function.

Analysis of olaparib resistant cell lines. *Molecular modeling.* Molecular models were generated by using PyMOL. Crystal structure data were obtained from RCSB Protein Data Bank (PDB). The codes for PARP1 structures were 4DQY (human PARP1 without ZN2 or BRCT domain) and 3ODC (human PARP1 ZN2).

Antibodies for immunoblotting. Anti-PARP1 (Cell Signalling, 9542; 1:1000 in TBST 5% milk), anti-HDAC1 (Abcam ab19845; 1:1000 in TBST 1% BSA), anti-PAR (Trevigen 4336-BPC-100, 1:1000 in PBST[0.05%Tween-20])

5% milk), and anti beta-actin (Cell Signaling #4970, 1:1000 in TBST 5% BSA) were incubated with western-blot membranes at 4 °C overnight with gentle rocking.

DNA binding assays. DNA binding of PARP1 was assayed by using a 26-bp palindromic DNA duplex (5'GCCTACCGGTTTCGCGAACCGGTAGGC3'³³) immobilized on Dynabeads™ M-280 Streptavidin (Invitrogen, 10 mg/ml). Individual incubations used 500 µg of protein extract and a buffer containing 10 mM HEPES (p.H. 7.4), MgCl₂ (1.5 mM), 25% glycerol, KCl (200 mM), EDTA (0.2 mM), Roche protease inhibitor cocktail (0.7X), DTT (0.5 mM) and AEBSF (0.1 mM). Experiments were repeated at least twice.

PARylation assay. Cells were treated with 6 µM olaparib overnight, followed 1 mM H₂O₂ for 10 minutes in the dark, washed with ice-cold PBS and collected. Cells were lysed in Laemmli buffer (120 mM TrisHCl pH6.8, 4% SDS, 20% glycerol) and lysates were separated on 4–20% Tris-Glycine gradient gel followed by transfer onto PVDF membrane. Membranes were immunoblotted with the appropriate antibodies. Experiments were repeated at least twice.

Data availability. The datasets generated and/or analysed during the current study are available in the European Nucleotide Archive (ENA) under the accession code PRJEB2977 (yeast) and PRJEB13612 (mouse). Access codes for specific samples are detailed in Supplementary Table 2. Source data for Figs 2 and 3 are provided in Supplementary Table S2; source data for Figs 4 and 5 are provided in Supplementary Table S3 and Supplementary Figure S3.

Code availability. Custom code used to analyse sequencing data and to draw figures is available in the following repository: <http://github.com/fabiopuddu/Herzog2018>.

References

- Hillenmeyer, M. E. *et al.* The chemical genomic portrait of yeast: uncovering a phenotype for all genes. *Science (New York, N.Y.)* **320**, 362–365 (2008).
- Parsons, A. B. *et al.* Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. *Cell* **126**, 611–625 (2006).
- Nijman, S. M. B. Functional genomics to uncover drug mechanism of action. *Nat. Chem. Biol.* **11**, 942–948 (2015).
- van Leeuwen, J. *et al.* Exploring genetic suppression interactions on a global scale. *Science (New York, N.Y.)* **354**, aag0839–aag0839 (2016).
- Forsburg, S. L. The art and design of genetic screens: yeast. *Nature reviews. Genetics* **2**, 659–668 (2001).
- Grimm, S. The art and design of genetic screens: mammalian culture cells. *Nature reviews. Genetics* **5**, 179–189 (2004).
- Horner, V. L. & Caspar, T. Creating a 'hopeful monster': mouse forward genetic screens. *Methods Mol. Biol.* **770**, 313–336 (2011).
- Trahey, M. & McCormick, F. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. *Science (New York, N.Y.)* **238**, 542–545 (1987).
- INGRAM, V. M. Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. *Nature* **180**, 326–328 (1957).
- Rolef Ben-Shahar, T. *et al.* Eco1-dependent cohesin acetylation during establishment of sister chromatid cohesion. *Science (New York, N.Y.)* **321**, 563–566 (2008).
- Carette, J. E. *et al.* Haploid genetic screens in human cells identify host factors used by pathogens. *Science (New York, N.Y.)* **326**, 1231–1235 (2009).
- Hsiang, Y. H., Hertzberg, R., Hecht, S. & Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. *The Journal of biological chemistry* **260**, 14873–14878 (1985).
- Bjornsti, M.-A., Benedetti, P., Viglianti, G. A. & Wang, J. C. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. *Cancer Res.* **49**, 6318–6323 (1989).
- Pommier, Y., Sun, Y., Huang, S.-Y. N. & Nitiss, J. L. Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. *Nature reviews. Molecular cell biology* **17**, 703–721 (2016).
- Rouse, J. Esc4p, a new target of Mec1p (ATR), promotes resumption of DNA synthesis after DNA damage. *The EMBO journal* **23**, 1188–1197 (2004).
- Puddu, F. *et al.* Synthetic viability genomic screening defines Sae2 function in DNA repair. *The EMBO journal* **34**, 1509–1522 (2015).
- Huertas, P., Cortés-Ledesma, F., Sartori, A. A., Aguilera, A. & Jackson, S. P. CDK targets Sae2 to control DNA-end resection and homologous recombination. *Nature* **455**, 689–692 (2008).
- Mimitou, E. P. & Symington, L. S. Ku prevents Exo1 and Sgs1-dependent resection of DNA ends in the absence of a functional MRX complex or Sae2. *EMBO J* **29**, 3358–3369 (2010).
- Coulondre, C. & Miller, J. H. Genetic studies of the lac repressor. IV. Mutagenic specificity in the lacI gene of *Escherichia coli*. *J. Mol. Biol.* **117**, 577–606 (1977).
- Reid, R. J., Kauh, E. A. & Bjornsti, M.-A. Camptothecin sensitivity is mediated by the pleiotropic drug resistance network in yeast. *The Journal of biological chemistry* **272**, 12091–12099 (1997).
- Puddu, F. *et al.* Chromatin determinants impart camptothecin sensitivity. *EMBO reports* e201643560, <https://doi.org/10.15252/embr.201643560> (2017).
- Mitchell, P. & Tollervey, D. An NMD pathway in yeast involving accelerated deadenylation and exosome-mediated 3'-5' degradation. *Molecular Cell* **11**, 1405–1413 (2003).
- Lynn, R. M., Bjornsti, M.-A., Caron, P. R. & Wang, J. C. Peptide sequencing and site-directed mutagenesis identify tyrosine-727 as the active site tyrosine of *Saccharomyces cerevisiae* DNA topoisomerase I. *Proc Natl Acad Sci USA* **86**, 3559–3563 (1989).
- Eng, W. K., Pandit, S. D. & Sternglanz, R. Mapping of the active site tyrosine of eukaryotic DNA topoisomerase I. *The Journal of biological chemistry* **264**, 13373–13376 (1989).
- Kumar, P., Henikoff, S. & Ng, P. C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nature protocols* **4**, 1073–1081 (2009).
- Yachdav, G. *et al.* PredictProtein—an open resource for online prediction of protein structural and functional features. *Nucleic acids research* **42**, W337–43 (2014).
- Redinbo, M. R., Stewart, L., Kuhn, P., Champoux, J. J. & Hol, W. G. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. *Science (New York, N.Y.)* **279**, 1504–1513 (1998).
- Stewart, L., Redinbo, M. R., Qiu, X., Hol, W. G. & Champoux, J. J. A model for the mechanism of human topoisomerase I. *Science (New York, N.Y.)* **279**, 1534–1541 (1998).

29. Forment, J. V. *et al.* Genome-wide genetic screening with chemically mutagenized haploid embryonic stem cells. *Nat. Chem. Biol.* **13**, 12–14 (2017).
30. Lord, C. J. & Ashworth, A. PARP inhibitors: Synthetic lethality in the clinic. *Science (New York, N.Y.)* **355**, 1152–1158 (2017).
31. Murai, J. *et al.* Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. *Cancer Res.* **72**, 5588–5599 (2012).
32. Langelier, M.-F., Planck, J. L., Roy, S. & Pascal, J. M. Crystal structures of poly(ADP-ribose) polymerase-1 (PARP-1) zinc fingers bound to DNA: structural and functional insights into DNA-dependent PARP-1 activity. *The Journal of biological chemistry* **286**, 10690–10701 (2011).
33. Langelier, M.-F., Planck, J. L., Roy, S. & Pascal, J. M. Structural basis for DNA damage-dependent poly(ADP-ribose)ylation by human PARP-1. *Science (New York, N.Y.)* **336**, 728–732 (2012).
34. Michel, A. H. *et al.* Functional mapping of yeast genomes by saturated transposition. *eLife* **6**, E3179 (2017).
35. Hardy, C. F., Dryga, O., Seematter, S., Pahl, P. M. & Sclafani, R. A. *mcm5/cdc46-bob1* bypasses the requirement for the S phase activator *Cdc7p*. *Proc Natl Acad Sci USA* **94**, 3151–3155 (1997).
36. Sandrock, T. M., O'Dell, J. L. & Adams, A. E. Allele-specific suppression by formation of new protein-protein interactions in yeast. *Genetics* **147**, 1635–1642 (1997).
37. Zhao, X., Chabes, A., Domkin, V., Thelander, L. & Rothstein, R. The ribonucleotide reductase inhibitor *Sml1* is a new target of the *Mec1/Rad53* kinase cascade during growth and in response to DNA damage. *The EMBO journal* **20**, 3544–3553 (2001).
38. Farmer, H. *et al.* Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* **434**, 917–921 (2005).
39. Bryant, H. E. *et al.* Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* **434**, 913–917 (2005).
40. Helleday, T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. *Mol Oncol* **5**, 387–393 (2011).
41. Pettitt, S. J. *et al.* A genetic screen using the PiggyBac transposon in haploid cells identifies *Parp1* as a mediator of olaparib toxicity. *PLoS one* **8**, e61520 (2013).
42. Leeb, M. & Wutz, A. Derivation of haploid embryonic stem cells from mouse embryos. *Nature* **479**, 131–134 (2011).
43. Elling, U. *et al.* Forward and reverse genetics through derivation of haploid mouse embryonic stem cells. *Cell Stem Cell* **9**, 563–574 (2011).
44. Munroe, R. & Schimenti, J. Mutagenesis of mouse embryonic stem cells with ethylmethanesulfonate. *Methods Mol. Biol.* **530**, 131–138 (2009).
45. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics (Oxford, England)* **25**, 1754–1760 (2009).
46. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics (Oxford, England)* **25**, 2078–2079 (2009).
47. McLaren, W. *et al.* Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. *Bioinformatics (Oxford, England)* **26**, 2069–2070 (2010).
48. Danecek, P. *et al.* The variant call format and VCFtools. *Bioinformatics (Oxford, England)* **27**, 2156–2158 (2011).
49. Narzisi, G. *et al.* Accurate de novo and transmitted indel detection in exome-capture data using microassembly. *Nature methods* **11**, 1033–1036 (2014).
50. Ng, P. C. & Henikoff, S. Predicting the effects of amino acid substitutions on protein function. *Annu Rev Genomics Hum Genet* **7**, 61–80 (2006).
51. Ng, P. C. & Henikoff, S. Predicting deleterious amino acid substitutions. *Genome research* **11**, 863–874 (2001).
52. Ng, P. C. & Henikoff, S. SIFT: Predicting amino acid changes that affect protein function. *Nucleic acids research* **31**, 3812–3814 (2003).

Acknowledgements

We thank Carmen Diaz Soria for help with the yeast screens; Josef Penninger for the gift of the AN3-12 mESC line; Carla Daniela Robles Espinoza and Martin del Castillo Velasco-Herrera for critical reading of the manuscript; James Hewinson for assistance with the submission for sequencing samples; and all the members of the SPJ laboratory for helpful discussions. This work was supported by Cancer Research UK [Programme Grant C6/A18796, Institute Core Funding C6946/A24843]; the Wellcome Trust [101126/Z/13/Z (Strategic Award - COMSIG), Investigator Award 206388/Z/17/Z, Institute Core Funding WT203144, PhD Fellowship 098051 to M.H.]; and the European Molecular Biology Organization [Long-Term Fellowship ALTF1287-2011 to F.P.].

Author Contributions

The project was conceived by J.V.F., F.P., M.H. and S.P.J. Yeast mutagenesis, suppressor screening, and DNA extractions were carried out by F.P. and N.J.G. Mouse haploid cell purification, E.M.S. mutagenesis, and screening were carried out by J.V.F.; DNA extractions and PARP assays were carried out by J.C. Analysis of yeast and mouse whole genome/exome sequencing data was carried out by F.P. and M.H., respectively. The manuscript was largely written by M.H., F.P., and S.P.J., with contributions made by all the other authors.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-018-24400-4>.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018